XASX
S66
Market cap13mUSD
Oct 07, Last price
0.14AUD
1D
0.00%
1Q
7.69%
IPO
-85.93%
Name
Star Combo Pharma Ltd
Chart & performance
P/E
47.90
P/S
0.80
EPS
0.00
Div yield, %
2.64%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-2.48%
Revenues
24m
-15.24%
Net income
395k
-92.48%
CFO
3m
-72.56%
Dividend
Oct 13, 20260.002961 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages the full spectrum of natural health supplements and skincare products, encompassing their development, manufacturing, promotion, and sale. Distribution channels include a dedicated e-commerce platform for health-conscious consumers in China, alongside two brick-and-mortar retail stores situated in Sydney. Founded in 2004, Star Combo Pharma Limited's main office is located in Smithfield, Australia.
Key people
Su Zhang
Chief Executive Officer, Director
James Ni
Chief Financial Officer · since 2022
Jinxing Zhang
Managing Director, Director · since 2016
Patrick Raper
Company Secretary
Jialong Ding
Non-Executive Director · since 2020
Wei Han
Non-Executive Director · since 2020
Ziye Sui
Non-Executive Director
Richard Allely
Non-Executive Independent Chairman of the Board · since 2018
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||